Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANEBNYSE:ANVSNASDAQ:ELEVNASDAQ:ONCY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANEBAnebulo Pharmaceuticals$1.15-3.4%$1.42$0.80▼$3.30$47.25M-1.0916,906 shs6,108 shsANVSAnnovis Bio$1.60+7.4%$2.47$1.43▼$20.00$22.78M1.65760,005 shs201,325 shsELEVElevation Oncology$0.26+5.9%$0.52$0.24▼$5.83$15.52M1.371.33 million shs2.01 million shsONCYOncolytics Biotech$0.52-0.8%$0.69$0.51▼$1.53$45.16M1.18514,101 shs200,908 shs20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANEBAnebulo Pharmaceuticals-3.36%-25.81%+3.60%-27.22%-59.36%ANVSAnnovis Bio+7.74%-13.98%-3.03%-68.69%-85.64%ELEVElevation Oncology+5.86%-0.42%-45.30%-55.97%-94.89%ONCYOncolytics Biotech-0.83%-16.16%-21.18%-43.79%-51.16%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANEBAnebulo Pharmaceuticals2.9061 of 5 stars3.55.00.00.02.81.70.0ANVSAnnovis Bio2.2756 of 5 stars3.52.00.00.02.31.70.6ELEVElevation Oncology2.7735 of 5 stars4.22.00.00.02.11.70.6ONCYOncolytics Biotech1.3389 of 5 stars3.53.00.00.00.60.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANEBAnebulo Pharmaceuticals 3.00Buy$8.00595.65% UpsideANVSAnnovis Bio 3.00Buy$37.002,212.50% UpsideELEVElevation Oncology 2.30Hold$3.391,192.26% UpsideONCYOncolytics Biotech 3.00Buy$4.00665.40% UpsideCurrent Analyst Ratings BreakdownLatest ANVS, ELEV, ONCY, and ANEB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/24/2025ELEVElevation OncologyStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$5.00 ➝ $1.003/21/2025ELEVElevation OncologyCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeMarket Perform3/21/2025ELEVElevation OncologyLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$9.00 ➝ $1.003/21/2025ELEVElevation OncologyCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform3/21/2025ELEVElevation OncologyPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$10.00 ➝ $0.703/21/2025ELEVElevation OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $1.003/20/2025ELEVElevation OncologyWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/20/2025ELEVElevation OncologyLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/10/2025ELEVElevation OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.003/10/2025ONCYOncolytics BiotechMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $3.003/10/2025ONCYOncolytics BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00(Data available from 4/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANEBAnebulo PharmaceuticalsN/AN/AN/AN/A$0.15 per shareN/AANVSAnnovis BioN/AN/AN/AN/A($0.73) per shareN/AELEVElevation OncologyN/AN/AN/AN/A$1.29 per shareN/AONCYOncolytics BiotechN/AN/AN/AN/A$0.27 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANEBAnebulo Pharmaceuticals-$8.20M-$0.28N/A∞N/AN/A-119.54%-108.08%5/13/2025 (Estimated)ANVSAnnovis Bio-$56.20M-$2.56N/AN/AN/AN/AN/A-311.00%5/12/2025 (Estimated)ELEVElevation Oncology-$45.70M-$0.81N/AN/AN/AN/A-59.73%-40.05%5/1/2025 (Estimated)ONCYOncolytics Biotech-$20.56M-$0.30N/AN/AN/AN/A-141.15%-84.73%5/8/2025 (Estimated)Latest ANVS, ELEV, ONCY, and ANEB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2025N/AELEVElevation Oncology-$0.20N/AN/AN/AN/AN/A4/4/2025N/AANVSAnnovis Bio-$0.38N/AN/AN/AN/AN/A3/21/2025Q4 2024ANVSAnnovis Bio-$0.38-$0.43-$0.05-$0.43N/AN/A3/6/2025Q4 2024ELEVElevation Oncology-$0.22-$0.18+$0.04-$0.18N/AN/A2/14/2025Q2 2025ANEBAnebulo PharmaceuticalsN/A-$0.09N/A-$0.09N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANEBAnebulo PharmaceuticalsN/AN/AN/AN/AN/AANVSAnnovis BioN/AN/AN/AN/AN/AELEVElevation OncologyN/AN/AN/AN/AN/AONCYOncolytics BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANEBAnebulo PharmaceuticalsN/A17.5117.51ANVSAnnovis BioN/A2.662.66ELEVElevation Oncology0.4517.7717.77ONCYOncolytics BiotechN/A2.992.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANEBAnebulo Pharmaceuticals28.40%ANVSAnnovis Bio15.83%ELEVElevation Oncology83.70%ONCYOncolytics Biotech6.82%Insider OwnershipCompanyInsider OwnershipANEBAnebulo Pharmaceuticals80.60%ANVSAnnovis Bio32.30%ELEVElevation Oncology8.10%ONCYOncolytics Biotech0.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANEBAnebulo Pharmaceuticals441.09 million5.79 millionNot OptionableANVSAnnovis Bio314.24 million9.64 millionOptionableELEVElevation Oncology4059.22 million54.33 millionOptionableONCYOncolytics Biotech3086.42 million85.42 millionNot OptionableANVS, ELEV, ONCY, and ANEB HeadlinesRecent News About These CompaniesWhat is HC Wainwright's Estimate for ONCY FY2027 Earnings?March 14, 2025 | marketbeat.comLeede Financial Has Positive Outlook of ONCY FY2025 EarningsMarch 14, 2025 | marketbeat.comHC Wainwright Cuts Earnings Estimates for Oncolytics BiotechMarch 13, 2025 | marketbeat.comMaxim Group Issues Pessimistic Forecast for Oncolytics Biotech (NASDAQ:ONCY) Stock PriceMarch 11, 2025 | marketbeat.comOncolytics Biotech's (ONCY) Buy Rating Reiterated at HC WainwrightMarch 11, 2025 | marketbeat.comRoyal Bank of Canada Cuts Oncolytics Biotech (NASDAQ:ONCY) Price Target to $5.00March 11, 2025 | marketbeat.comOncolytics price target lowered to $3 from $5 at MaximMarch 10, 2025 | markets.businessinsider.comOncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2024 Earnings Call TranscriptMarch 8, 2025 | msn.comOncolytics Biotech (NASDAQ:ONCY) Announces Quarterly Earnings ResultsMarch 8, 2025 | marketbeat.comOncolytics Biotech Inc. (ONCY) Q4 2024 Earnings Call TranscriptMarch 7, 2025 | seekingalpha.comOncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024March 7, 2025 | prnewswire.comOncolytics Biotech (ONCY) Loses -9.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerMarch 5, 2025 | zacks.comOncolytics Biotech Inc. (NASDAQ:ONCY) Short Interest Down 14.1% in FebruaryMarch 5, 2025 | marketbeat.comWorld Cancer Day Sparks Big Questions About Pollution, Genetics, and InnovationFebruary 27, 2025 | baystreet.caUSA News Group: Oncology Breakthroughs: How Cancer Research Is Advancing in 2025February 27, 2025 | finanznachrichten.deOncolytics Biotech to Discuss 2024 Financial Results and Operational HighlightsFebruary 25, 2025 | tipranks.comOncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational HighlightsFebruary 25, 2025 | prnewswire.comOncolytics Biotech advances pancreatic, anal cancer trialsFebruary 20, 2025 | markets.businessinsider.comUSA News Group: Investors Eye Biotech Sector as Cancer Therapy Market SurgesFebruary 19, 2025 | finanznachrichten.deOncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025February 19, 2025 | prnewswire.comOncolytics provides progress update for pelareorep in pancreatic and anal cancerFebruary 18, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWarren Buffett Swaps VOO for This Reliable Dividend StockBy Sarah Horvath | March 7, 2025View Warren Buffett Swaps VOO for This Reliable Dividend StockNVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyBy Thomas Hughes | March 12, 2025View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyBYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?By Jeffrey Neal Johnson | March 21, 2025View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?3 Defense Stocks Set to Benefit From Increased Military SpendingBy Chris Markoch | March 20, 2025View 3 Defense Stocks Set to Benefit From Increased Military SpendingWhich Healthcare Stock Is the Best Buy Right Now?By Nathan Reiff | March 31, 2025View Which Healthcare Stock Is the Best Buy Right Now?ANVS, ELEV, ONCY, and ANEB Company DescriptionsAnebulo Pharmaceuticals NASDAQ:ANEB$1.15 -0.04 (-3.36%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$1.11 -0.04 (-3.48%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.Annovis Bio NYSE:ANVS$1.60 +0.11 (+7.38%) Closing price 04/2/2025 03:58 PM EasternExtended Trading$1.52 -0.08 (-5.25%) As of 08:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.Elevation Oncology NASDAQ:ELEV$0.26 +0.01 (+5.86%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$0.26 0.00 (-0.76%) As of 08:32 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.Oncolytics Biotech NASDAQ:ONCY$0.52 0.00 (-0.83%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$0.51 -0.01 (-2.22%) As of 08:22 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 5 Reasons Why Halliburton is a Good Buy in 2025 First Watch Restaurant Group: A First-Rate Small-Cap Growth Stock Tesla Stock: What To Expect With Their Delivery Numbers Report Rocket Lab: $5.6 Billion Defense Contract Fuels RKLB’s Future Analyst Targets Signal More Growth in CrowdStrike Stock NextEra Energy Stock Sees Spike in Bullish Call Activity 2 Reasons to Buy Apple Stock and 1 Significant Risk Salesforce: The Most Resilient Software Stock for Downturns Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
